LPS-triggered Mφ production of NO during acute and nonlethal GVHD
| Treatment in vitro . | Normal B6AF1 . | Nitrite in Mφ culture supernatants (μmol/L) . | |||
|---|---|---|---|---|---|
| Nonlethal GVHD B6AF1 . | Acute GVHD B6AF1 . | ||||
| Day 7 . | Day 14 . | Day 7 . | Day 14 . | ||
| Medium | < 1 | < 1 | < 1 | < 1 | < 1 |
| LPS 2.5 ng/mL | 1.9 ± 0.5 | 14.9 ± 5.8 | 5.4 ± 1.4 | 18.1 ± 2.9 | 45.0 ± 4.3 |
| LPS 2.5 ng/mL + IFN-γ | 50.5 ± 5.1 | 42.8 ± 5.1 | 54.4 ± 3.8 | 31.7 ± 3.0 | 58.1 ± 7.1 |
| LPS 2.5 ng/mL + anti–IFN-γ | < 1 | 14.3 ± 1.4 | 2.4 ± 0.5 | 12.4 ± 1.1 | 35.5 ± 3.1 |
| LPS 2.5 ng/mL + IFN-γ + anti–IFN-γ | 4.7 ± 1.4 | 14.1 ± 5.5 | 7.0 ± 2.0 | 9.3 ± 5.4 | 30.5 ± 3.6 |
| LPS 2.5 ng/mL L-arginine-free medium | < 1 | < 1 | < 1 | < 1 | < 1 |
| Treatment in vitro . | Normal B6AF1 . | Nitrite in Mφ culture supernatants (μmol/L) . | |||
|---|---|---|---|---|---|
| Nonlethal GVHD B6AF1 . | Acute GVHD B6AF1 . | ||||
| Day 7 . | Day 14 . | Day 7 . | Day 14 . | ||
| Medium | < 1 | < 1 | < 1 | < 1 | < 1 |
| LPS 2.5 ng/mL | 1.9 ± 0.5 | 14.9 ± 5.8 | 5.4 ± 1.4 | 18.1 ± 2.9 | 45.0 ± 4.3 |
| LPS 2.5 ng/mL + IFN-γ | 50.5 ± 5.1 | 42.8 ± 5.1 | 54.4 ± 3.8 | 31.7 ± 3.0 | 58.1 ± 7.1 |
| LPS 2.5 ng/mL + anti–IFN-γ | < 1 | 14.3 ± 1.4 | 2.4 ± 0.5 | 12.4 ± 1.1 | 35.5 ± 3.1 |
| LPS 2.5 ng/mL + IFN-γ + anti–IFN-γ | 4.7 ± 1.4 | 14.1 ± 5.5 | 7.0 ± 2.0 | 9.3 ± 5.4 | 30.5 ± 3.6 |
| LPS 2.5 ng/mL L-arginine-free medium | < 1 | < 1 | < 1 | < 1 | < 1 |
Mφ were collected on the day indicated, incubated for 48 hours, and the concentration of nitrite in culture supernatants was determined. Nonlethal GVHD received 30 × 106, and acute GVHD received 60 × 106 B6 cells. Results are the mean ± SEM of 3 experiments. For treatment with 2.5-ng/mL LPS, P < .001 on day 7 compared with day 14 for acute GVHD, and P < .001 for nonlethal GVHD compared with acute GVHD on day 14.